Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Vedolizumab SC in UC and CD
NCT02620046Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2016
- Primary completion
- Jun 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 33
01
Overview
A Phase 3 trial of vedolizumab in ulcerative colitis (UC), Crohn's disease, sponsored by Takeda. Started Apr 2016; status: completed.
02
Drugs
vedolizumab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT02620046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02620046.